Every FDA decision, trial change and new guide in rare disease, recorded day by day and published each Monday.
to · Issue 30 · The latest week
Klygefa, Myqorzo, Gazyva and Pimjetmi approved, and 153 trial changes across 65 conditions
In the week of Nov 9th we recorded 153 changes to rare disease trials on ClinicalTrials.gov, 4 FDA decisions, and no trial that opened to new patients.
The week in 5 lines
- 153 updates to rare disease trials, across 65 conditions. 8 trials stopped enrolling.
- 4 FDA approvals: Klygefa for generalized myasthenia gravis, Myqorzo (label update) for obstructive hypertrophic cardiomyopathy, Gazyva for primary membranous nephropathy, Pimjetmi for tenosynovial giant cell tumor.
- 1 drug label was updated.
- 5 new guides on Trial Friend.
- Next FDA decision: Molbreevi, due November 22, 2026.
- NOV9Mon · 202631trial changes, 1 guide
- NOV10Tue · 2026ApprovalPimjetmi, plus 45 changes
- NOV11Wed · 20262trial changes, 1 guide
- NOV12Thu · 202645trial changes, 1 guide
- NOV13Fri · 20263 approvalsKlygefa, Myqorzo, Gazyva, plus 30 changes
- NOV14Sat · 20260trial changes
- NOV15Sun · 20260trial changes
FDA decisions, November 9 to November 15
Each links to its page on the FDA calendar, with the date, what changed and the source.
- Approved. Pimjetmi (Pimicotinib) for Tenosynovial giant cell tumor (TGCT)A medicine not approved before. · Tenosynovial Giant Cell Tumor
- Approved. Klygefa (Gefurulimab) for Generalized myasthenia gravis (anti-AChR antibody-positive adults)A medicine not approved before. · Myasthenia Gravis
- Label update approved. Myqorzo for Obstructive hypertrophic cardiomyopathy, adding the MAPLE-HCM trialThe drug was already approved for this condition; its label now carries new information. · Familial Hypertrophic Cardiomyopathy
- New use approved. Gazyva for Primary membranous nephropathyThe drug was already approved for another condition. · Membranous Nephropathy
Trials that opened and closed, November 9 to November 15
Status changes recorded on ClinicalTrials.gov this week, 8 in all
- No longer enrolling. Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT)… (GeneCradle)Spinal Muscular Atrophy
- No longer enrolling. Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue… (University Health Network, Toronto)Fabry Disease
- No longer enrolling. Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim (Vanderbilt University Medical Center)Duchenne Muscular Dystrophy
- No longer enrolling. Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) (Ascidian Therapeutics)Stargardt Disease
- No longer enrolling. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab… (European Myeloma Network B.V.)Multiple Myeloma
- No longer enrolling. Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or… (City of Hope Medical Center)Multiple Myeloma
- No longer enrolling. Bionic Pancreas in CFRD (Jaeb Center for Health Research)cystic fibrosis
- No longer enrolling. Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With… (City of Hope Medical Center)Multiple Myeloma
Results, funds, designations and label changes that week
- FDA approved a label update for GavretoRET Fusion Cancer · FDA
Free email alert
Follow a condition from this issue by email
Tap one of this week's conditions or search for yours, and we email you when one of its trials changes or the FDA acts. Some weeks that is nothing, and we never pad.
You'll get trial alerts and disease updates, and you can turn either off anytime. We never share your email. Privacy policy
How this issue is made
Every trial change comes from ClinicalTrials.gov, read twice a day for the conditions Trial Friend follows, and every FDA decision, designation and label change from the FDA's own records, Drugs@FDA and openFDA, read daily. Each line links to the page that holds its source. The issue is assembled on the Monday after the week and does not change afterwards, except to correct an error, which is noted on the page. Counts cover only the rare conditions on this site, so they are a floor for rare disease as a whole, not a total. Nothing here is medical advice.
Past weeks
Every issue stays here at its own address. The archive begins with the first week we recorded, the week of April 20, 2026.
- #30Week of November 9thKlygefa approved for Generalized myasthenia gravis, Myqorzo approved for Obstructive hypertrophic cardiomyopathy, MAPLE-HCM label update, 5 new guides4 5
- #29Week of November 2nd6 new guides6
- #28Week of October 26thVoceryq is approved for RRP, three myasthenia gravis trials close to new patients, and Kite's CAR-T reaches past myeloma1 3
- #27Week of October 19thUltomiris approved for IgA nephropathy, 7 new guides1 7
- #26Week of October 12thEnspryng approved for Thyroid eye disease, 10 new guides1 10
- #25Week of October 5th5 new guides5
- #24Week of September 28thCamzyos approved for Obstructive hypertrophic cardiomyopathy, adolescents, Emcitate approved for MCT8 deficiency, 9 new guides2 9
- #23Week of September 21stAtebrioz approved for Fibrodysplasia ossificans progressiva, Gazyva approved for Idiopathic nephrotic syndrome, 9 new guides3 9
- #22Week of September 14thAqneursa approved for Ataxia-telangiectasia, Fayuvi approved for Sanfilippo syndrome type A, 9 new guides2 9
- #21Week of September 7thIsembyld approved for Spinal muscular atrophy, Joenja approved for Activated PI3K delta syndrome (APDS), children 4 to 11, 5 new guides2 5
- #20Week of August 31stZanvastro approved for Alexander disease1
- #19Week of August 24thBesremi approved for Essential thrombocythemia, Mimrylo approved for Polycythemia vera, 1 new guide4 1
- #18Week of August 17thGenglycos approved for Glycogen storage disease type 1a, Pasatru approved for Fibrodysplasia ossificans progressiva2
- #17Week of August 10thTrial changes across the conditions we follow
- #16Week of August 3rdOrzeyful approved for Narcolepsy type 11
- #15Week of July 27thTrial changes across the conditions we follow
- #14Week of July 20thTrial changes across the conditions we follow
- #13Week of July 13thFabhalta approved for IgA nephropathy1
- #12Week of July 6thTrutakna approved for IgA nephropathy1
- #11Week of June 29thTrial changes across the conditions we follow
- #10Week of June 22ndTrial changes across the conditions we follow
- #9Week of June 15thTrial changes across the conditions we follow
- #8Week of June 8thTrial changes across the conditions we follow
- #7Week of June 1stTrial changes across the conditions we follow
- #6Week of May 25th1 new guide1
- #5Week of May 18th1 new guide1
- #4Week of May 11th1 new guide1
- #3Week of May 4th4 new guides4
- #2Week of April 27th4 new guides4
- #1Week of April 20th2 new guides2